The Hypolipemic Properties of 2-Acetoamidoethyl (p-chlorophenyl) (m-trifluoromethylphenoxy) acetate in the Rat

doi:10.3181/00379727-136-35474

Paper

The Hypolipemic Properties of 2-Acetoamidoethyl (p-chlorophenyl) (m-trifluoromethylphenoxy) acetate in the Rat

Published Apr 1, 1971 · J. Gilfillan, V. Hunt, J. Huff

Proceedings of the Society for Experimental Biology and Medicine

UNKNOWN SJR score

12

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Summary 2-Acetoamidoethyl (p-chlorophenyl) (m-trifluoromethylphenoxy) acetate (halofenate) has been established as a potent hypolipemic agent in the rat, significantly lowering, in a dose-response relationship, plasma cholesterol, triglycerides, phospholipids, and free-fatty acids.

Study Snapshot

2-Acetoamidoethyl (p-chlorophenyl) (m-trifluoromethylphenoxy) acetate (halofenate) is a potent hypolipemic agent in rats, significantly lowering plasma cholesterol, triglycerides, phospholipid

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

The Hypolipemic Properties of 2-Acetoamidoethyl (p-chlorophenyl) (m-trifluoromethylphenoxy) acetate in the Rat

References

Citations

Serum and liver lipid responses to 3-hydroxy-3-methylglutaric acid in rats on different carbohydrate diets

HMG significantly lowers cholesterol and triglyceride levels in rats on all types of carbohydrate diets, with more marked effects in glucose, fructose, sucrose, and lactose.

Tissue lipid responses to 3-hydroxy-3-methylglutaric acid with different dietary fats

HMG administration for 4 weeks with a 20% saturated fat diet effectively prevents serum cholesterol, triglyceride, and phospholipid increases, while decreasing triglyceride levels in serum, liver, aorta, and heart.

Halofenate: a potent inhibitor of normal and hypersensitive platelets.

Halofenate is a more potent inhibitor of platelet aggregation than clofibrate, potentially reversing increased platelet sensitivity in cardiovascular diseases.

Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.

Halofenate and clofibrate effectively reduce serum triglyceride levels in the rat by inhibiting hepatic triglyceride formation.

New drugs affecting lipid metabolism

New drugs affecting lipid metabolism include SU 13,437, Sah 42-348, halofenate, treloxinate, S-8527, and two valeric acid derivatives.